Catheter Precision, Inc. Forms new Joint Venture Called Kardionav to Exploit patented AI Techniques to Create New VT Software platform
Catheter Precision (NYSE:VTAK) has announced the formation of a new joint venture called Kardionav to develop advanced AI-powered software for ventricular tachycardia (VT) ablation. The venture combines VTAK's expertise with Chelak iECG to enhance VT treatment outcomes through improved mapping technology.
The ownership structure allocates 56% to VTAK, 33% to Chelak iECG, and 10% to management. Dr. Jie Cheng, founder of Chelak iECG and Clinical Professor at Baylor College of Medicine, will serve as the primary researcher, bringing significant AI and arrhythmia localization expertise to the venture.
The joint venture aims to develop a standalone ventricular mapping system that will integrate vector technology with imaging of conduction channels and velocity calculations. This next-generation technology builds upon VTAK's existing VIVO platform and seeks to address current limitations in VT ablation procedures, including lengthy procedure times and imprecise ablation site targeting.
Catheter Precision (NYSE:VTAK) ha annunciato la creazione di una nuova joint venture chiamata Kardionav, dedicata allo sviluppo di un software avanzato basato su intelligenza artificiale per l'ablazione della tachicardia ventricolare (VT). Questa iniziativa unisce l'esperienza di VTAK a quella di Chelak iECG per migliorare i risultati del trattamento della VT attraverso tecnologie di mappatura avanzate.
La struttura proprietaria prevede una quota del 56% per VTAK, 33% per Chelak iECG e 10% per il management. Il dott. Jie Cheng, fondatore di Chelak iECG e Professore Clinico presso il Baylor College of Medicine, sarà il ricercatore principale, apportando una significativa esperienza in intelligenza artificiale e localizzazione delle aritmie.
La joint venture punta a sviluppare un sistema di mappatura ventricolare autonomo che integrerà la tecnologia vettoriale con l'imaging dei canali di conduzione e i calcoli di velocità. Questa tecnologia di nuova generazione si basa sulla piattaforma VIVO di VTAK e mira a superare le attuali limitazioni nelle procedure di ablazione della VT, come i tempi prolungati e la scarsa precisione nell'individuazione dei siti di ablazione.
Catheter Precision (NYSE:VTAK) ha anunciado la formación de una nueva empresa conjunta llamada Kardionav, destinada a desarrollar un software avanzado impulsado por inteligencia artificial para la ablación de taquicardia ventricular (VT). Esta alianza combina la experiencia de VTAK con Chelak iECG para mejorar los resultados del tratamiento de la VT mediante tecnología de mapeo mejorada.
La estructura de propiedad asigna un 56% a VTAK, un 33% a Chelak iECG y un 10% a la gerencia. El Dr. Jie Cheng, fundador de Chelak iECG y Profesor Clínico en el Baylor College of Medicine, será el investigador principal, aportando una amplia experiencia en inteligencia artificial y localización de arritmias.
La empresa conjunta tiene como objetivo desarrollar un sistema de mapeo ventricular independiente que integrará tecnología vectorial con imágenes de canales de conducción y cálculos de velocidad. Esta tecnología de próxima generación se basa en la plataforma VIVO de VTAK y busca superar las limitaciones actuales en los procedimientos de ablación de VT, incluyendo tiempos prolongados y la imprecisión en la localización de los sitios de ablación.
Catheter Precision (NYSE:VTAK)는 심실 빈맥(VT) 절제를 위한 첨단 AI 기반 소프트웨어를 개발하기 위해 Kardionav라는 새로운 합작 회사를 설립했다고 발표했습니다. 이 합작 회사는 VTAK의 전문성과 Chelak iECG의 기술을 결합하여 향상된 매핑 기술을 통해 VT 치료 결과를 개선하는 것을 목표로 합니다.
소유 구조는 VTAK가 56%, Chelak iECG가 33%, 경영진이 10%를 보유합니다. Chelak iECG의 창립자이자 Baylor 의과대학 임상 교수인 Jie Cheng 박사가 주요 연구원으로 참여하여 AI 및 부정맥 위치 지정 분야에서 풍부한 전문 지식을 제공합니다.
이 합작 회사는 벡터 기술과 전도 채널 영상 및 속도 계산을 통합한 독립형 심실 매핑 시스템을 개발하는 것을 목표로 합니다. 이 차세대 기술은 VTAK의 기존 VIVO 플랫폼을 기반으로 하며, 긴 시술 시간과 부정확한 절제 부위 지정 등 현재 VT 절제 절차의 한계를 극복하고자 합니다.
Catheter Precision (NYSE:VTAK) a annoncé la création d'une nouvelle coentreprise nommée Kardionav, destinée à développer un logiciel avancé propulsé par intelligence artificielle pour l'ablation de la tachycardie ventriculaire (TV). Cette initiative combine l'expertise de VTAK avec celle de Chelak iECG afin d'améliorer les résultats du traitement de la TV grâce à une technologie de cartographie améliorée.
La structure de propriété répartit 56 % à VTAK, 33 % à Chelak iECG et 10 % à la direction. Le Dr Jie Cheng, fondateur de Chelak iECG et professeur clinique au Baylor College of Medicine, sera le chercheur principal, apportant une expertise significative en IA et localisation des arythmies.
La coentreprise vise à développer un système de cartographie ventriculaire autonome qui intégrera la technologie vectorielle avec l'imagerie des canaux de conduction et les calculs de vitesse. Cette technologie de nouvelle génération s'appuie sur la plateforme VIVO existante de VTAK et cherche à surmonter les limites actuelles des procédures d'ablation de la TV, notamment les durées d'intervention prolongées et le ciblage imprécis des sites d'ablation.
Catheter Precision (NYSE:VTAK) hat die Gründung eines neuen Joint Ventures namens Kardionav bekannt gegeben, das fortschrittliche KI-gestützte Software für die Ablation der ventrikulären Tachykardie (VT) entwickeln soll. Das Unternehmen vereint die Expertise von VTAK mit Chelak iECG, um die Behandlungsergebnisse bei VT durch verbesserte Mapping-Technologie zu optimieren.
Die Eigentümerstruktur sieht 56 % für VTAK, 33 % für Chelak iECG und 10 % für das Management vor. Dr. Jie Cheng, Gründer von Chelak iECG und klinischer Professor am Baylor College of Medicine, wird als Hauptforscher fungieren und bringt umfangreiche Erfahrung in KI und Arrhythmie-Lokalisierung mit.
Das Joint Venture hat das Ziel, ein eigenständiges ventrikuläres Mapping-System zu entwickeln, das Vektortechnologie mit der Bildgebung von Leitungskanälen und Geschwindigkeitsberechnungen kombiniert. Diese nächste Generation Technologie baut auf der bestehenden VIVO-Plattform von VTAK auf und soll die aktuellen Einschränkungen bei VT-Ablationsverfahren überwinden, wie lange Prozedurzeiten und ungenaue Zielbestimmung der Ablationsstellen.
- None.
- Current VT ablation procedures have significant limitations including lengthy times and poor outcomes
- Existing treatments often result in declined ventricular function without curing VT
Insights
Catheter Precision forms Kardionav JV to develop AI-driven VT ablation mapping technology that could significantly improve treatment outcomes.
Catheter Precision (VTAK) has established a strategic joint venture called Kardionav with Chelak iECG to develop advanced AI technology for ventricular tachycardia (VT) ablation procedures. The ownership structure gives VTAK 56% control, with Chelak iECG holding 33% and management retaining 10%.
This venture represents a significant technological advancement in the cardiac electrophysiology space. Current VT ablation procedures suffer from multiple limitations: they're lengthy, require putting patients in and out of VT, lack precise ablation targeting, and often result in diminished ventricular function without fully addressing the arrhythmia.
What makes this partnership particularly promising is the combination of VTAK's existing VIVO technology with Chelak's AI and intellectual property. The joint technology aims to provide more precise localization of ventricular arrhythmias, imaging of conduction channels, and calculation of conduction velocity. These advancements could potentially transform treatment outcomes by enabling more targeted ablation rather than the current "carpet bombing" approach.
The venture benefits significantly from the expertise of Dr. Jie Cheng, who brings impressive credentials as both a cardiac electrophysiologist and biomedical engineer with training from prestigious institutions. His dual background in medicine and engineering positions him ideally to lead the technical development of this AI-driven mapping system.
While other companies are developing improved VT-specific ablation catheters, Kardionav's focus on precise localization addresses a critical gap in the treatment pathway that could dramatically improve procedural success rates, potentially creating a valuable new segment in the electrophysiology market.
New AI techniques to add to VT ablation tools
FORT MILL, S.C., June 30, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market today announced that it has formed a joint venture, named Kardionav, to pursue the latest in technology surrounding the area of ablation for ventricular tachycardia. The venture is a joint development company between VTAK and Chelak iECG, Inc., whereby both companies will contribute intellectual property and know-how. VTAK will own approximately
Jie Cheng, PhD, MD, is the president and founder of Chelak iECG, and will contribute to the venture as the primary researcher. Dr. Cheng commented, “We have some significant research and IP around AI and pinpointing the exact location of ventricular arrhythmias to enhance patient outcomes in ventricular ablation. Our desire is to bring technology into a standalone Ventricular mapping system, with the goal to shorten treatment procedure times with better outcomes. VT is not well treated today, and we believe that Kardionav can change that. This joint venture will allow us to combine resources and expedite technological development.”
Dr. Cheng is a practicing cardiac electrophysiologist and engineer. He holds a PhD in Biomedical Engineering from Case Western Reserve University, and has medical training at Mt. Sinai Medical Center, Case Western Reserve University, University of Chicago, and the University of California at San Francisco. He currently holds the position of Clinical Professor of Medicine at Baylor College of Medicine, and President and Medical Director of Texas Heart Rhythm Center, and is Senior Research Scientist and Director of the Electrophysiology Research Laboratory at the Texas Heart Institute in Houston, Texas.
David Jenkins, CEO of Catheter Precision, commented on the new venture, “We could not be more excited about the opportunity that Kardionav brings to us. This will be the next generation of our VIVO technology and will combine vector technology with additional inputs for the physician including imaging of channels of conduction and calculation of velocity of conduction. Today’s ablation techniques in the ventricle leave much to be desired. Procedures are lengthy, the patients are put in and out of VT for long periods of time, the site of ablation is not well defined, and, as a result, the method of “carpet bombing” without great outcomes, and often, resulting in a decline of ventricular function, while not curing the VT, are all parameters of VT ablation today. Other companies are developing improved VT specific ablation catheters, but without the precise localization to be provided by Kardionav, the advanced catheters do little to bring about better patient outcomes and growth in this new segment of EP.”
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at www.sec.gov.
The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
CONTACTS:
At the Company
Investor Relations
973-691-2000
IR@catheterprecision.com
# # #
FAQ
What is the ownership structure of the new Kardionav joint venture?
Who is leading the research at Kardionav?
What technology improvements does Kardionav aim to bring to VT treatment?
What are the current limitations of VT ablation that Kardionav seeks to address?
How does this joint venture relate to VTAK's existing technology?
